TCH-P (also written TCHP) is a four-drug chemotherapy regimen used to treat HER2-positive breast cancer. The acronym stands for its four components: docetaxel (T), carboplatin (C), trastuzumab (H, sold as Herceptin), and pertuzumab (P, sold as Perjeta). It combines two traditional chemotherapy drugs with two targeted antibody therapies, and it’s one of the preferred treatment options recommended by the National Comprehensive Cancer Network for HER2-positive breast cancer.
What the Four Drugs Do
The power of TCHP comes from attacking cancer cells through multiple pathways at once. About 20% of breast cancers overproduce a protein called HER2 on the surface of their cells, which fuels rapid growth. TCHP targets that vulnerability from several angles.
Trastuzumab binds directly to the HER2 protein on cancer cells, blocking the growth signals it sends and flagging those cells for destruction by the immune system. Pertuzumab attaches to a different spot on the same HER2 protein, preventing it from pairing up with related proteins that would otherwise activate survival pathways. Together, these two antibodies create a more complete blockade than either could alone.
Docetaxel and carboplatin handle the cytotoxic side of treatment. Docetaxel disrupts the internal scaffolding cancer cells need to divide. Carboplatin is a platinum-based drug that damages the DNA inside cancer cells, triggering cell death. These two chemotherapy agents kill rapidly dividing cells directly, while the antibodies cut off the growth signals that keep HER2-positive tumors thriving.
When TCHP Is Used
TCHP is most commonly given as neoadjuvant therapy, meaning it’s administered before surgery to shrink the tumor. The goal is to reduce the amount of cancer present before a lumpectomy or mastectomy, which can make surgery less extensive and improve long-term outcomes. It can also be used in the adjuvant setting (after surgery) or for locally advanced disease.
In the KRISTINE clinical trial, TCHP achieved a pathologic complete response rate of 55.7%. That means more than half of patients had no detectable cancer remaining in the breast or lymph nodes by the time they went to surgery. A complete response to neoadjuvant treatment is a strong predictor of long-term survival in HER2-positive breast cancer.
What a Treatment Cycle Looks Like
TCHP is given in six cycles, each lasting 21 days. On day one of each cycle, all four drugs are administered through an IV infusion. The first session tends to be the longest because the antibodies are infused slowly to watch for reactions. Subsequent infusions are typically faster once your care team confirms you tolerate the drugs well.
On day two, most patients receive an injection of a white blood cell booster (pegfilgrastim) to help the immune system recover between cycles. Docetaxel-based regimens carry a 22% to 36% risk of causing a dangerous drop in infection-fighting white blood cells, so this growth factor support is considered standard. You’ll either receive it at the clinic or learn to administer the injection at home.
The full course of six cycles takes roughly 18 weeks from start to finish. After completing TCHP, most patients continue trastuzumab and pertuzumab (without the chemotherapy drugs) for a total of one year of antibody therapy.
Common Side Effects
Hair loss is one of the most visible side effects of TCHP and happens to nearly everyone on the regimen. It typically begins within a few weeks of the first infusion and can come on gradually or quite quickly. Hair usually starts growing back three to four weeks after the last chemotherapy cycle, appearing first as soft fuzz. By two to three months, most people have about an inch of new growth. It can take a full year to reach four to six inches, and the new hair sometimes comes in with a different texture or color than before.
Fatigue is another near-universal experience, often worsening with each cycle. Nausea, changes in taste, mouth sores, and diarrhea are common but generally manageable with the anti-nausea medications given alongside treatment. Carboplatin can lower platelet counts, so you may bruise more easily or notice that cuts take longer to stop bleeding. Many people also experience numbness or tingling in the fingers and toes from docetaxel, a side effect called peripheral neuropathy that sometimes lingers after treatment ends.
Heart Monitoring During Treatment
Both trastuzumab and pertuzumab can affect heart function, so cardiac monitoring is built into the treatment plan. Before starting TCHP, you’ll have a baseline heart scan, typically an echocardiogram, to measure how well your heart pumps. This measurement is called the left ventricular ejection fraction (LVEF).
During treatment, heart function is generally checked every three months. After treatment ends, monitoring continues every six months for at least two years. If a scan shows a significant drop in pumping ability, your oncologist may pause or adjust the antibody therapy to let the heart recover. The reassuring news is that heart effects from these drugs are usually reversible once treatment is modified, unlike some older chemotherapy agents that can cause permanent damage. Patients without pre-existing cardiovascular risk factors have a low risk of developing symptomatic heart problems, around 0.4% in some analyses.
Life During TCHP
Most people continue some of their normal activities during TCHP, though the week following each infusion tends to be the hardest. Days two through five after treatment are often when fatigue, body aches, and nausea peak. Many patients describe a pattern of feeling worst during the first week, gradually improving during the second, and feeling closest to normal during the third week, just before the next cycle begins.
Your immune system will be at its lowest point roughly seven to ten days after each infusion. During this window, avoiding crowded indoor spaces and people who are sick can help prevent infections. Fever during this period is taken seriously and typically warrants a call to your oncology team, since your body may not be able to fight infections as effectively.
Between the growth factor injection, anti-nausea medications, and scheduled blood work, TCHP involves a fair amount of clinic time beyond the infusion days themselves. Blood draws before each cycle check your white blood cell counts, kidney function, and liver enzymes to confirm your body is ready for the next round. Occasionally a cycle is delayed by a week if blood counts haven’t recovered enough.